EX-99.2 3 d531920dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

APPENDIX 4E - PRELIMINARY FINAL REPORT    

 

LOGO

1. Company details

 

Name of entity:    Kazia Therapeutics Limited
ABN:    37 063 259 754
Reporting period:    For the year ended 30 June 2023
Previous period:    For the year ended 30 June 2022

2. Results for announcement to the market

 

           2022               
     2023     restated     Change      Change       
      $     $     $      %       

  Loss from ordinary activities after tax attributable to the

  owners of Kazia Therapeutics Limited

      (20,465,180 )      (25,014,055 )      4,548,875        (18%)      

  Loss for the year attributable to the owners of Kazia

  Therapeutics Limited

      (20,465,180 )      (25,014,055 )      4,548,875        (18%)      

3. Net tangible assets

 

     Reporting     Previous       
     period     period       
      Cents     Cents       

Net tangible assets per ordinary security

      (2.29 )      (0.62)      

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Kazia Therapeutics (Hong Kong) Limited - Deregistered and dissolved on 10 March 2023.

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

 

Kazia Theraputics Limited Appendix 4E 2023                    i

APPENDIX 4E - PRELIMINARY FINAL REPORT    

 

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unqualified opinion with an emphasis of matter around going concern has been issued.

11. Attachments

Details of attachments (if any):

The Directors’ report and financial statements of Kazia Therapeutics Limited for the year ended 30 June 2023 is attached.

12. Signed

 

LOGO

                                                                                                                                                                                                                                                                                                                                   
Dr John Friend
Interim Chairman, Managing
Director, Chief Executive Officer
Date: 31 August 2023

 

Kazia Theraputics Limited Appendix 4E 2023                    ii